Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2024
0mins
Should l Buy SCLX?
Source: Newsfilter
Merger Announcement: Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, has signed a merger agreement with Denali Capital Acquisition Corp., valuing Semnur at $2.5 billion, aiming to create a publicly traded biopharma company focused on non-opioid pain management products.
Product Development: The merger will support the development of SP-102 (SEMDEXA™), a novel injectable corticosteroid gel for treating sciatica, which has shown promising Phase 3 trial results and is projected to generate annual sales of $1.5 billion to $2 billion by its fifth year post-launch.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCLX
About SCLX
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scilex Announces Dividend of Dream Bowl Tokens to Shareholders
- Dividend Announcement: Scilex's Board approved the distribution of Dream Bowl I Meme Coin Tokens to shareholders, with a record date of April 30, 2026, allowing participants to receive five tokens per share held, which is expected to enhance shareholder value with approximately 81.4 million tokens distributed.
- Distribution Conditions: Participants must open a digital wallet with Datavault AI Inc. and sign an Opt-In Agreement to ensure they understand the token receipt process and potential changes, reflecting the company's commitment to transparency and compliance.
- Market Liquidity Expectations: Scilex intends to list the Dream Bowl Tokens on the Biconomy exchange, which is anticipated to enhance liquidity and broaden distribution among holders, potentially attracting more investor interest in the company's innovative products.
- Token Nature Clarification: The Dream Bowl Token is intended solely for personal, non-commercial use and does not confer any equity or financial rights, emphasizing its function as a digital collectible to mitigate investment risks and clarify the company's strategic direction.
See More
SCILEX HOLDING CO PLANS TO LAUNCH DREAM BOWL TOKENS ON BICONOMY EXCHANGE
- Company Announcement: Cilex Holding Co. intends to list Dream Bowl tokens on the Biconomy exchange.
- Market Impact: This move is expected to enhance the visibility and trading opportunities for Dream Bowl tokens in the cryptocurrency market.
See More
SCILEX HOLDING COMPANY DECLARES DIVIDEND OF DREAM BOWL I MEME COIN TOKENS FOR COMMON STOCKHOLDERS AND OTHER QUALIFIED EQUITY SECURITY HOLDERS, RECORD DATE SET FOR APRIL 30, 2026
- Dividend Announcement: Cilex Holding Company has announced a dividend of Dream Bowl Lime Meme Coin to holders of common stock and other eligible equity securities.
- Record Date: The record date for this dividend distribution is set for April 30, 2026.
See More
SCILEX HOLDING CO FACES COMPLAINT OVER UNAUTHORIZED SALE OF PLEDGED DVLT SHARES THROUGH BNY MELLON ACCOUNTS - SEC FILING
Complaint Filed: A complaint has been filed against CILEX Holding Co. alleging unauthorized sale of pledged DVLTS shares.
Involvement of SEC: The complaint has been submitted to the SEC, indicating regulatory scrutiny over the transaction.
See More
Scilex Makes $20 Million Strategic Investment in Quantum Scan
- Strategic Investment: Scilex Holding Company announced a $20 million strategic investment in Quantum Scan Holdings, Inc., aimed at supporting the development of innovative medical technologies in preventive diagnosis and prognosis, which is expected to enhance the company's competitiveness in this trillion-dollar market.
- Support for Technological Innovation: This investment will enable Quantum Scan to develop advanced diagnostic platforms and scalable healthcare solutions, improving accessibility and efficiency in healthcare delivery, thereby addressing the growing market demand and enhancing patient care experiences.
- Synergistic Effects: Scilex believes this investment complements its substantial investment in Datavault AI, further solidifying its strategic positioning in the non-opioid pain management sector and driving overall business growth.
- Leadership Confidence: Quantum Scan CEO Mustaq Patel stated that Scilex's investment will accelerate their innovation in medical technologies, reflecting confidence in their team and vision, indicating potential for long-term value creation within the healthcare ecosystem.
See More
Scilex Appoints Kasowitz LLP as Legal Counsel for IP and Litigation
- Legal Counsel Appointment: Scilex has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the company's litigation and intellectual property counsel, aimed at strengthening its legal capabilities in complex commercial and patent litigation to better protect its proprietary pharmaceutical assets and development pipeline.
- Intellectual Property Strategy: Kasowitz LLP will advise Scilex on intellectual property enforcement and defense, licensing matters, and strategic governance, which will assist the company in maintaining its market position during the commercialization of non-opioid pain management products.
- Industry Expertise: Marc Kasowitz is a highly experienced U.S. trial lawyer with decades of experience in complex commercial litigation, including representation in intellectual property disputes involving innovative technologies and life sciences, providing robust legal support for Scilex.
- Long-term Strategic Value: A spokesperson for Scilex stated that protecting and enforcing the intellectual property portfolio is central to the company's long-term strategy and shareholder value, and the appointment of Kasowitz will further enhance its legal capabilities in commercializing products and advancing its late-stage pipeline.
See More
Scilex Announces Dividend of Dream Bowl Tokens to Shareholders
- Dividend Announcement: Scilex's Board approved the distribution of Dream Bowl I Meme Coin Tokens to shareholders, with a record date of April 30, 2026, allowing participants to receive five tokens per share held, which is expected to enhance shareholder value with approximately 81.4 million tokens distributed.
- Distribution Conditions: Participants must open a digital wallet with Datavault AI Inc. and sign an Opt-In Agreement to ensure they understand the token receipt process and potential changes, reflecting the company's commitment to transparency and compliance.
- Market Liquidity Expectations: Scilex intends to list the Dream Bowl Tokens on the Biconomy exchange, which is anticipated to enhance liquidity and broaden distribution among holders, potentially attracting more investor interest in the company's innovative products.
- Token Nature Clarification: The Dream Bowl Token is intended solely for personal, non-commercial use and does not confer any equity or financial rights, emphasizing its function as a digital collectible to mitigate investment risks and clarify the company's strategic direction.
See More
SCILEX HOLDING CO PLANS TO LAUNCH DREAM BOWL TOKENS ON BICONOMY EXCHANGE
- Company Announcement: Cilex Holding Co. intends to list Dream Bowl tokens on the Biconomy exchange.
- Market Impact: This move is expected to enhance the visibility and trading opportunities for Dream Bowl tokens in the cryptocurrency market.
See More
SCILEX HOLDING COMPANY DECLARES DIVIDEND OF DREAM BOWL I MEME COIN TOKENS FOR COMMON STOCKHOLDERS AND OTHER QUALIFIED EQUITY SECURITY HOLDERS, RECORD DATE SET FOR APRIL 30, 2026
- Dividend Announcement: Cilex Holding Company has announced a dividend of Dream Bowl Lime Meme Coin to holders of common stock and other eligible equity securities.
- Record Date: The record date for this dividend distribution is set for April 30, 2026.
See More
SCILEX HOLDING CO FACES COMPLAINT OVER UNAUTHORIZED SALE OF PLEDGED DVLT SHARES THROUGH BNY MELLON ACCOUNTS - SEC FILING
Complaint Filed: A complaint has been filed against CILEX Holding Co. alleging unauthorized sale of pledged DVLTS shares.
Involvement of SEC: The complaint has been submitted to the SEC, indicating regulatory scrutiny over the transaction.
See More
Scilex Makes $20 Million Strategic Investment in Quantum Scan
- Strategic Investment: Scilex Holding Company announced a $20 million strategic investment in Quantum Scan Holdings, Inc., aimed at supporting the development of innovative medical technologies in preventive diagnosis and prognosis, which is expected to enhance the company's competitiveness in this trillion-dollar market.
- Support for Technological Innovation: This investment will enable Quantum Scan to develop advanced diagnostic platforms and scalable healthcare solutions, improving accessibility and efficiency in healthcare delivery, thereby addressing the growing market demand and enhancing patient care experiences.
- Synergistic Effects: Scilex believes this investment complements its substantial investment in Datavault AI, further solidifying its strategic positioning in the non-opioid pain management sector and driving overall business growth.
- Leadership Confidence: Quantum Scan CEO Mustaq Patel stated that Scilex's investment will accelerate their innovation in medical technologies, reflecting confidence in their team and vision, indicating potential for long-term value creation within the healthcare ecosystem.
See More
Scilex Appoints Kasowitz LLP as Legal Counsel for IP and Litigation
- Legal Counsel Appointment: Scilex has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the company's litigation and intellectual property counsel, aimed at strengthening its legal capabilities in complex commercial and patent litigation to better protect its proprietary pharmaceutical assets and development pipeline.
- Intellectual Property Strategy: Kasowitz LLP will advise Scilex on intellectual property enforcement and defense, licensing matters, and strategic governance, which will assist the company in maintaining its market position during the commercialization of non-opioid pain management products.
- Industry Expertise: Marc Kasowitz is a highly experienced U.S. trial lawyer with decades of experience in complex commercial litigation, including representation in intellectual property disputes involving innovative technologies and life sciences, providing robust legal support for Scilex.
- Long-term Strategic Value: A spokesperson for Scilex stated that protecting and enforcing the intellectual property portfolio is central to the company's long-term strategy and shareholder value, and the appointment of Kasowitz will further enhance its legal capabilities in commercializing products and advancing its late-stage pipeline.
See More
